Ajay Dhaygude

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Frailty and chronic kidney disease: current evidence and continuing uncertainties

Andrew Nixon, Theodoros M. Bampouras, Neil Pendleton et al. · Clinical Kidney Journal · 2017 · 214 citations · Full text

Fried Phenotype Model, Hemodialysis, Urology +14

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy

Neill Duncan, Ajay Dhaygude, Joel Owen et al. · Nephrology Dialysis Transplantation · 2004 · 90 citations

Frailty is independently associated with worse health-related quality of life in chronic kidney disease: a secondary analysis of the Frailty Assessment in Chronic Kidney Disease study

Andrew Nixon, Theodoros M. Bampouras, Neil Pendleton et al. · Clinical Kidney Journal · 2019 · 56 citations · Full text